FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVA									
OMP Number:	222E U3								

287 Estimated average burden 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Sectio	n 30(h)	of thè	Ínve	estment (Com	pany Act	of 19	940							
1. Name and Address of Reporting Person* DIXON WENDY L						2. Issuer Name and Ticker or Trading Symbol Eleven Biotherapeutics, Inc. [EBIO]										eck a	all applic	p of Reporting Person(s) to Issu blicable)			
						_										X	Directo	•		10% Ov	
	(F EVEN BIO		3. Date of Earliest Transaction (Month/Day/Year) 05/19/2017											Officer below)	r (give title ')		Other (s below)	pecify			
245 FIRST STREET, SUITE 1800				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. 1	6. Individual or Joint/Group Filing (Check Applicable						
(Street) CAMBRIDGE MA 02142					-										Line	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																		
		Tab	le I - Noi	n-Deriv	ative	Sec	curitie	s Ac	cqui	ired, D	isp	osed c	of, o	r Ben	eficial	ly O	wned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.					ar) E	2A. Deemed Execution Date, f any Month/Day/Yea		•,	3. Transact Code (In: 8)	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			(A) or . 3, 4 and	4 and Se Be Ow		5. Amount of Securities Beneficially Dwned Following Reported		: Direct (Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	,	Amount	t (A) or (D)		Price	1	Transaction(s) (Instr. 3 and 4)				(1130.4)
		٦	Table II -	Deriva (e.g., p												Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year				7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		4)	Deri Sec	s. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	Code V		(D)	Date Exe	e ercisable		piration ite	Title	1	Amount or Number of Shares						

\$1.48

1. The option was granted on May 19, 2017 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.

8,072

Remarks:

Stock

Option

/s/ John J. McCabe as attorney-05/23/2017 in-fact

8,072

\$0

8,072

D

** Signature of Reporting Person

Common

Stock

05/18/2027

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/19/2017

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.